MAP2K3 and colorectal carcinoma: In this perspective, our finding that high MKK3 levels are expressed especially in late stage CRC patients, which normally rely on chemotherapy as a therapeutic option39, prompts towards a rapid evaluation of MKK3-targeting potential in improving the therapeutic outcome in these patients.